EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer

Soohyun Lee iD, Hwa-Ryeon Kim, Yaejin Woo, Jiyoung Kim, Han Wool Kim, Ji Youn Park, Beomseon Suh, Yuri Choi, Jungmin Ahn, Je Ho Ryu, Jae-Seok Roe, Jaewhan Song und 1 weitere

Advanced Science · 2024-09 · 11 (33)

DOI: 10.1002/advs.202400398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 03.07.2024. Verfasst von Soohyun Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ubix Therapeutics, Seoul, 05836, Republic of Korea. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Androgen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Brain Korea 21 FOUR Program, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The androgen receptor (AR) is an attractive target for treating prostate cancer, considering its role in the development and progression of localized and metastatic prostate cancer. The high global mortality burden of prostate cancer, despite medical treatments such as androgen deprivation or AR antagonist therapy, highlights the need to explore alternative strategies. One strategy involves the use of heterobifunctional degraders, also known as proteolysis‐targeting chimeras, which are novel small‐molecule therapeutics that inhibit amplified or mutated targets. Here, the study reports a novel cereblon‐based AR degrader, UBX‐390, and demonstrates its superior activity over established AR degraders, such as ARV‐110 or ARCC‐4, in prostate cancer cells under short‐ and long‐term treatment conditions. UBX‐390 suppresses chromatin binding and gene expression of AR and demonstrates substantial efficacy in the degradation of AR mutants in patients with treatment‐resistant prostate cancer. UBX‐390 is presented as an optimized AR degrader with remarkable potential for treating castration‐resistant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsReceptors, AndrogenMaleHumansCell Line, TumorAnimalsAndrogen Receptor AntagonistsMiceDisease Models, AnimalProteolysis

Stichwörter der Autor:innen

PROTACandrogen receptorcancer therapydegraderprostate cancer

Substanzen

Receptors, AndrogenAndrogen Receptor AntagonistsAR protein, human

Autor:innen und Institutionen

  • Ubix Therapeutics, Seoul, 05836, Republic of Korea.
  • Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.

ORCID-Profile: Soohyun Lee, Song Hee Lee

Förderung

  • National Research Foundation of Korea
  • Brain Korea 21 FOUR Program
  • Ministry of Education

Zitieren

APA

Lee, S., Kim, H. R., Woo, Y., Kim, J., Kim, H. W., Park, J. Y., Suh, B., Choi, Y., Ahn, J., Ryu, J. H., Roe, J. S., Song, J., & Lee, S. H. (2024). UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer. Advanced Science, 11(33). https://doi.org/10.1002/advs.202400398

Vancouver

Lee S, Kim HR, Woo Y, Kim J, Kim HW, Park JY, et al. UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer. Advanced Science. 2024;11(33). doi:10.1002/advs.202400398

BibTeX
@article{Lee2024,
  author = {Lee, Soohyun and Kim, Hwa-Ryeon and Woo, Yaejin and Kim, Jiyoung and Kim, Han Wool and Park, Ji Youn and Suh, Beomseon and Choi, Yuri and Ahn, Jungmin and Ryu, Je Ho and Roe, Jae-Seok and Song, Jaewhan and Lee, Song Hee},
  title = {UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {33},
  doi = {10.1002/advs.202400398}
}
Kostenlos starten →